Hudson Bay Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Hudson Bay Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$360K	Sell	9,700 -42,130	-81%	-$1.28M	﹤0.01%	1047
2026 Q1	$1.75M	Sell	51,830 -48,170	-48%	-$1.37M	0.01%	790
2025 Q4	$2.72M	Sell	100,000 -22,500	-18%	-$789K	0.01%	648
2025 Q3	$4.92M	Sell	122,500 -7,500	-6%	-$282K	0.02%	554
2025 Q2	$4.32M	Buy	130,000 +19,280	+17%	+$584K	0.01%	580
2025 Q1	$3.24M	Buy	110,720 +720	+0.7%	+$23.9K	0.01%	706
2024 Q4	$3.61M	Buy	110,000 +50,000	+83%	+$2.35M	0.01%	561
2024 Q3	$2.67M	Sell	60,000 -55,000	-48%	-$2.5M	0.01%	531
2024 Q2	$4.96M	Sell	115,000 -292,500	-72%	-$10.6M	0.02%	379
2024 Q1	$11.9M	Sell	407,500 -82,500	-17%	-$2.21M	0.07%	156
2023 Q4	$10.9M	Buy	490,000 +220,000	+81%	+$4.93M	0.07%	169
2023 Q3	$6.68M	Buy	270,000 +10,000	+4%	+$265K	0.05%	225
2023 Q2	$7.36M	Sell	260,000 -10,000	-4%	-$249K	0.05%	225
2023 Q1	$6.2M	Buy	270,000 +60,000	+29%	+$1.59M	0.05%	261
2022 Q4	$5.9M	Buy	210,000 +30,000	+17%	+$845K	0.06%	311
2022 Q3	$5.09M	Sell	180,000 -163,500	-48%	-$4.39M	0.05%	399
2022 Q2	$7.62M	Buy	343,500 +118,500	+53%	+$2.68M	0.06%	263
2022 Q1	$6.55M	Buy	225,000 +25,000	+13%	+$764K	0.09%	268
2021 Q4	$6.57M	Buy	200,000 +125,000	+167%	+$5.03M	0.07%	251
2021 Q3	$3.46M	Buy	75,000 +20,000	+36%	+$966K	0.05%	479
2021 Q2	$3.03M	Sell	55,000 -30,000	-35%	-$1.68M	0.04%	502
2021 Q1	$4.39M	Sell	85,000 -95,088	-53%	-$4.71M	0.05%	337
2020 Q4	$7.8M	Buy	180,088 +42,588	+31%	+$1.68M	0.08%	147
2020 Q3	$4.81M	Buy	137,500 +102,500	+293%	+$4.49M	0.07%	239
2020 Q2	$1.87M	Buy	+35,000	New	+$1.62M	0.03%	322
2020 Q1	–	Sell	-70,000	Closed	-$3.34M	–	490
2019 Q4	$3.34M	Buy	70,000 +40,000	+133%	+$1.51M	0.07%	227
2019 Q3	$972K	Buy	+30,000	New	+$1.24M	0.03%	322
2019 Q2	–	Sell	-15,000	Closed	-$1.01M	–	411
2019 Q1	$1.01M	Buy	+15,000	New	+$874K	0.01%	555

Other funds holding AGIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Hudson Bay Capital Management's AGIO Position: Q2 2026 in Review

Hudson Bay Capital Management reduced its Agios Pharmaceuticals (AGIO) stake by 81% in Q2 2026, selling an estimated $1.28M and leaving 9,700 shares worth $360K. The position accounts for ﹤0.01% of the portfolio, ranked #1047.

Hudson Bay Capital Management first reported a position in AGIO in Q1 2019 and has held it in 28 quarters since. The position peaked at $11.9M in Q1 2024. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

Hudson Bay Capital Management held 9,700 shares of Agios Pharmaceuticals worth $360K as of Q2 2026.
Hudson Bay Capital Management sold 42,130 Agios Pharmaceuticals shares in Q2 2026, an estimated $1.28M.
Agios Pharmaceuticals made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #1047 holding.
Hudson Bay Capital Management first reported a position in Agios Pharmaceuticals in Q1 2019 and has held it in 28 quarters since.
Hudson Bay Capital Management's Agios Pharmaceuticals position peaked at $11.9M in Q1 2024.
238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.